Evidence map›Paper›PMID 29554336›Full record

ArticleMedical mycology2018

Flucytosine resistance in Cryptococcus gattii is indirectly mediated by the FCY2-FCY1-FUR1 pathway.

Kiem Vu, George R Thompson, Chandler C Roe, Jane E Sykes, Elizabeth M Dreibe, Shawn R Lockhart, Wieland Meyer, David M Engelthaler, Angie Gelli

Open access · greenAbstract read
In one paragraph

Article in Medical mycology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
2.1field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 20 citations in OpenAlex.

  1. RapidmSphere · 2025
    Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Review
  10. Article
  11. Flucytosine and its clinical usage.Therapeutic advances in infectious disease
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 5 institutions in 2 countries.

Kiem VuDepartment of Pharmacology, University of California, Davis, California, USA.
George R ThompsonDepartment of Medical Microbiology and Immunology, University of California, Davis, California, USA.
Chandler C RoeTranslational Genomics Research Institute, Flagstaff, Arizona, USA.
Jane E SykesDepartment of Medicine and Epidemiology, School of Veterinary Medicine, University of California, Davis, California, USA.
Elizabeth M DreibeTranslational Genomics Research Institute, Flagstaff, Arizona, USA.
Shawn R LockhartMycotic Diseases Branch, Centers for Disease Control and Prevention, Atlanta, Georgia USA.
Wieland MeyerMolecular Mycology Research Laboratory, Center for Infectious Diseases and Microbiology, Marie Bashir Institute for Emerging Infectious Diseases and Biosecurity, Westmead Clinical School, Sydney Medical School, Westmead Hospital, The University of Sydney, Westmead Institute for Medical Research, Sydney, Australia.
David M EngelthalerTranslational Genomics Research Institute, Flagstaff, Arizona, USA.
Angie GelliDepartment of Pharmacology, University of California, Davis, California, USA.
Translational Genomics Research Institute · USUniversity of California, Davis · USCenters for Disease Control and Prevention · USThe University of Sydney · AUUniversity of California Davis Medical Center · US

Funding

Fungal calcium channels as therapeutic targets for AIDS-associated opportunisticR01AI078848 · NIAID · UNIVERSITY OF CALIFORNIA AT DAVIS · PI GELLI, ANGIE · 2009 to 2011
$1.1M
NIAID NIH HHS R01 AI078848
6 · The paper itself

Abstract

Cryptococcosis is an opportunistic fungal infection caused by members of the two sibling species complexes: Cryptococcus neoformans and Cryptococcus gattii. Flucytosine (5FC) is one of the most widely used antifungals against Cryptococcus spp., yet very few studies have looked at the molecular mechanisms responsible for 5FC resistance in this pathogen. In this study, we examined 11 C. gattii clinical isolates of the major molecular type VGIII based on differential 5FC susceptibility and asked whether there were genomic changes in the key genes involved in flucytosine metabolism. Susceptibility assays and sequencing analysis revealed an association between a point mutation in the cytosine deaminase gene (FCY1) and 5FC resistance in two of the studied 5FC resistant C. gattii VGIII clinical isolates, B9322 and JS5. This mutation results in the replacement of arginine for histidine at position 29 and occurs within a variable stretch of amino acids. Heterologous expression of FCY1 and spot sensitivity assays, however, demonstrated that this point mutation did not have any effect on FCY1 activities and was not responsible for 5FC resistance. Comparative sequence analysis further showed that no changes in the amino acid sequence and no genomic alterations were observed within 1 kb of the upstream and downstream sequences of either cytosine permeases (FCY2-4) or uracil phosphoribosyltransferase (FUR1) genes in 5FC resistant and 5FC susceptible C. gattii VGIII isolates. The herein obtained results suggest that the observed 5FC resistance in the isolates B9322 and JS5 is due to changes in unknown protein(s) or pathway(s) that regulate flucytosine metabolism.

Indexed as

Protein Interaction MapsAntifungal AgentsCryptococcosisCryptococcus gattiiCytosine DeaminaseDNA Mutational AnalysisFlucytosineFungal ProteinsHumansMaleMembrane Transport ProteinsMicrobial Sensitivity TestsPentosyltransferasesSequence Analysis, DNAAntifungal AgentsCytosine DeaminaseFlucytosineFungal ProteinsMembrane Transport ProteinsPentosyltransferasesuracil phosphoribosyltransferase

Identifiers

PMID29554336
PMCPMC10905989
OpenAlexW2902279515

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.